• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Piper Sandler resumed coverage on Solid Biosciences with a new price target

    5/31/24 7:48:22 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SLDB alert in real time by email
    Piper Sandler resumed coverage of Solid Biosciences with a rating of Overweight and set a new price target of $20.00
    Get the next $SLDB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLDB

    DatePrice TargetRatingAnalyst
    1/8/2025$16.00Buy
    Truist
    12/13/2024$16.00Outperform
    Wedbush
    12/10/2024$15.00Mkt Outperform
    JMP Securities
    7/15/2024$10.00 → $15.00Neutral → Overweight
    JP Morgan
    6/24/2024$12.00Market Perform → Outperform
    Leerink Partners
    5/31/2024$20.00Overweight
    Piper Sandler
    3/28/2024$40.00Outperform
    William Blair
    3/15/2024$16.00Buy
    Citigroup
    More analyst ratings

    $SLDB
    SEC Filings

    See more
    • Solid Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Solid Biosciences Inc. (0001707502) (Filer)

      6/13/25 4:21:19 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Solid Biosciences Inc.

      S-8 - Solid Biosciences Inc. (0001707502) (Filer)

      6/13/25 4:02:48 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Solid Biosciences Inc.

      EFFECT - Solid Biosciences Inc. (0001707502) (Filer)

      5/28/25 12:15:12 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 34,550 restricted stock units ("RSUs") to two newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducement

      6/3/25 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

      CHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, at 2:00 pm ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 30 days on the Events page. Institutional investors interested in meeting with ma

      5/28/25 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

      - Duchenne (SGT-003): Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant anticipated in the second half of 2025 - - CPVT (SGT-501): FDA IND on track for submission first half of 2025 - - Cash: Company ended first quarter 2025 with $306.9 million in cash, cash equivalents, investments and available-for-sale securities; Solid has anticipated cash runway into the first half of 2027 - CHARLESTOWN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision, next gen

      5/15/25 4:06:47 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Solid Biosciences with a new price target

      Truist initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00

      1/8/25 8:30:04 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Solid Biosciences with a new price target

      Wedbush initiated coverage of Solid Biosciences with a rating of Outperform and set a new price target of $16.00

      12/13/24 8:18:51 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Solid Biosciences with a new price target

      JMP Securities initiated coverage of Solid Biosciences with a rating of Mkt Outperform and set a new price target of $15.00

      12/10/24 8:02:56 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kahn Clare bought $9,924 worth of shares (1,860 units at $5.34), increasing direct ownership by 169% to 2,960 units (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      3/13/25 4:05:03 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Bain Capital Life Sciences Investors, Llc bought $4,030,000 worth of shares (1,000,000 units at $4.03) (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      2/21/25 5:48:02 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Perceptive Advisors Llc bought $20,150,000 worth of shares (5,000,000 units at $4.03) (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      2/21/25 4:17:42 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Keresty Georgia

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      6/18/25 4:05:04 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Stone Adam Leo

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      6/13/25 5:06:25 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Perceptive Advisors Llc

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      6/13/25 5:05:50 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

      SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 7:59:25 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Solid Biosciences Inc.

      SC 13G - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 12:02:53 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Solid Biosciences Inc.

      SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 8:56:19 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care